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Abstract
Myocardial damage as a consequence of cardiotropic viruses leads to a broad variety of clinical presentations and is
still a complicated condition to diagnose and treat. Whereas the extracellular matrix protein Secreted Protein Acidic
and Rich in Cysteine or SPARC has been implicated in hypertensive and ischemic heart disease by modulating
collagen production and cross-linking, its role in cardiac inflammation and endothelial function is yet unknown.
Absence of SPARC in mice resulted in increased cardiac inflammation and mortality, and reduced cardiac
systolic function upon coxsackievirus-B3 induced myocarditis. Intra-vital microscopic imaging of the microvas-
culature of the cremaster muscle combined with electron microscopic imaging of the microvasculature of
the cardiac muscle uncovered the significance of SPARC in maintaining endothelial glycocalyx integrity and
subsequent barrier properties to stop inflammation. Moreover, systemic administration of recombinant SPARC
restored theendothelial glycocalyx andconsequently reversed the increase in inflammation andmortality observed
in SPARC KO mice in response to viral exposure. Reducing the glycocalyx in vivo by systemic administration
of hyaluronidase, an enzyme that degrades the endothelial glycocalyx, mimicked the barrier defects found in
SPARC KO mice, which could be restored by subsequent administration of recombinant SPARC.
In conclusion, the secreted glycoprotein SPARC protects against adverse cardiac inflammation andmortality by
improving the glycocalyx function and resulting endothelial barrier function during viral myocarditis.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Myocarditis is defined as inflammation of the heart
muscle and can be caused by a variety of infectious
and non-infectious illnesses. Amongst the infectious
causes, viruses are supposedly the most frequent
pathogens affecting the myocardium. The broad
variety of clinical presentations,makeviralmyocarditis
a complicated condition to diagnose and treat. Despite
combining the standardized criteria for histological
diagnosis of myocarditis [1] with endomyocardial
biopsy [2], the true incidence is still not precisely
known yet, estimating 1 to 10 cases per 100,000
persons each year.
Not only can acute viral myocarditis lead to sudden
cardiac arrest [5], but it is also a major cause of
congestive heart failure [6] and in some cases even
requires cardiac transplantation. Responsible cardi-
otropic viruses, such as the entero-coxsackie B
viruses, can induce this severe cardiac inflammation
in susceptible patients, resulting in heart failure and
possibly sudden death. This form of heart disease is
0022-2836/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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particularly devastating as it affects previously healthy
young adults. In spite of our better understanding of
the causative cardiotropic viruses and consecutive
immunological mechanisms that contribute to the
development of cardiac dysfunction [7], diagnosis and
treatment for myocarditis are still poor. Elucidating the
underlying mechanisms of enhanced or sustained
cardiac inflammation can facilitate the development
of new specific therapies for viral myocarditis.
The cardiac extracellular matrix (ECM), comprised
of proteoglycans, glycoproteins and glycosamino-
glycans [8], plays an important role in intercellular
communication during cardiac disease [9,10]. Since
inflammation and heart failure reciprocally trigger
one another [11], we speculated that ECM proteins
may trigger heart failure development by potentiating
the immune response [12,13]. When addressing the
interaction of the immune system and the ECM in
cardiac disease however, the prominent vascular
gatekeeper known as the endothelial glycocalyx is
often overlooked. This while the endothelial glycoca-
lyx is comprised of similar proteoglycans, glycopro-
teins and glycosaminoglycans to the cardiac ECM
and is known to regulate inflammation, vascular
permeability, coagulation and mechanotransduction
[14,15]. The endothelial glycocalyx does not just
infer the luminal lining of the endothelium but in
fact encapsulates endothelial cells and expand
towards the endothelial basement membrane [14].
Therefore, we investigated the role of the endothe-
lial glycocalyx in regulating inflammation in viral
myocarditis in this study with a specific focus on
ECM protein Secreted Protein Acidic and Rich in
Cysteine (SPARC).
SPARC has been shown to regulate fibroblast
function in connective tissue [16–19] as well as
tumour development and progression [20,21], bone
homeostasis and repair [22], angiogenesis [23] and
cardiac ageing [18,24,25]. Moreover, both in vitro
studies and in vivo murine oncology studies have
recognized the increased vascular permeability in
the absence of SPARC [26,27], however the mech-
anisms by which SPARC may influence vascular
permeability are still unclear. Where SPARC has
been recognized for its fundamental roles as an
adhesive component of the ECM, no attention has
been given to the extracellular lining of the endothe-
lium as a possible immune-regulating structure
housing SPARC [14]. As the expression of SPARC
is low during normal post-natal life but dramatically
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Fig. 1. SPARC is needed to limit cardiac inflammation during viral myocarditis. (A,B) CD45 staining and quantification
of left ventricular sections 7 days after CVB3 injection showing increased cardiac leukocytes in SPARC KO hearts
(***p = 0.0005 One-way ANOVA, n = 11 and 10 for WT and KO respectively). (C) No difference was found in viral load
between both genotypes. (D) Survival of SPARC KO andWT animals during CVB3 infection suggest increased mortality
in SPARC KO mice (mortality: 7/12 in SPARC KO versus 4/14 in WT, p = 0.06 using Mantel-Cox method). (E,F) FACS
analysis of circulating and cardiac leukocytes (CD45+ cells), granulocytes, monocytes and lymphocyte populations
shows no differences between SPARC KO and WT mice in sham animals (E). However, while circulating leukocytes
numbers remain unchanged four days after injection with CVB3 between genotypes, the amount of cardiac Ly6Chi
monocytes and granulocytes were significantly increased in the SPARCKOmice as compared toWTmice (F, *p ≤ 0.01,
student's t-test). Scale bar: 200 μm.
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upregulated upon tissue injury, we contemplated
that SPARC may influence cardiac inflammation in
viral myocarditis and could therefore potentially be
used as a therapeutic strategy limiting heart failure
development.
The present study reveals that SPARC regulates
inflammation, vascular permeability, and consequent-
ly mortality in a murine coxsackievirus B3 (CVB3)
induced myocarditis model by regulating the integrity
of the endothelial glycocalyx. Above all, this study
emphasizes the vital role of the endothelial glycocalyx
as part of the extracellular matrix in cardiac (patho-)
physiology.
Results
Absence of SPARC increased cardiac
inflammation andmortality in viral myocarditis and
accelerated the onset of dilated cardiomyopathy
As a first step in investigating the role of SPARC
during cardiac inflammation, we subjected SPARC
KO and WT mice to CVB3-induced viral myocarditis.
Virus-mediated cardiomyocyte damage will induce
the infiltration of innate leukocytes (macrophages/
monocytes and granulocytes), which is followed by
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Fig. 2. SPARC is needed to maintain vascular barrier properties. (A) SPARC showed positive staining in blood vessels
coinciding Platelet endothelial cell adhesion molecule (PECAM-1) also known as cluster of differentiation 31 (CD31),
vascular cell adhesion molecule-1 (VCAM-1) and with Wheat Germ Agglutinin (WGA lectin specific for all sialic acid and
N-acetylglucosamine that are present on glycoproteins within the extracellular space), but not with CD45+ leukocytes in the
heart during viral myocarditis. All images shown are representative, scale bar: 50 μm. (B) Labelledmicro-beads were injected
and visualized after counterstaining with vascular endothelial cadherin (VE-cadherin) revealing more extravasation in
SPARC-KO animals. (Representative picture, red: micro-beads, green: VE-cadherin, scale = 20 μm, n = 3 per group)
(C) Systemic injection of Evans Blue resulted in significantly more uptake of Evans Blue in the myocardium of SPARC KO
sham animals compared toWT shamanimals (n = 8, 6 forWT andKO respectively, *p b 0.005, Student t-test). (D) Pull down
of SPARC with protein A/G heparin coated sepharose beads in a cardiac endothelial cell lysate. The input in the first lane
represents the total cell lysate. The second lane (depleted) shows the total cell lysate after incubation with the heparin coated
sepharose beads. After an empty lane, the fourth lane then represents the pull down with the heparin sepharose beads.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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adaptive leukocytes (B- and T-lymphocytes). We
found that significantly more innate and adaptive
leukocytes (CD45 positive) infiltrated the heart of
SPARC KO mice as compared to WT mice at day 7
(0.7 ± 0.2% vs 6.8 ± 1.8% positive staining of total
left ventricular area for WT and KO respectively;
p b 0.005 (Fig. 1A–B)). Furthermore, absence of
SPARC led to increased mortality (9/21, 43% in KO
vs. 11/14, 72% in WT at 7 days; p = 0.06) (Fig. 1C).
The viral exposure did not differ as cardiac viral
presence was similar in SPARC KO as compared to
WT mice during peak viremia (day 2) (Fig. 1C).
While CVB3 injures cardiomyocytes, tissue destruc-
tion can be potentiated by the recognition of this
virus by pattern recognition receptors of the innate
and adaptive immune system, resulting in the pro-
duction of inflammatory cytokines. Therefore, we
measured the expression of viral pattern recognition
receptors Toll-Like-Receptor 3 (TLR3), melanoma
differentiation association protein-5 (MDA-5) and
retinoic acid inducible gene-1 (RIG-1) and found
no difference between both groups (Supplemental
Fig. 1A–C).
Next, we investigated whether absence of SPARC
would affect the recruitment of innate and/or adap-
tive leukocytes to the injured myocardium. The
number of leukocytes either in the circulation or
in cardiac tissue under normal conditions did not
significantly differ between SPARCWT and KOmice
before CVB3 infection as revealed by flow cytometry
(Fig. 1E). However, as a consequence of viral infec-
tion, a rapid recruitment of innate immune cells
into the hearts of SPARC KO mice was observed
(83,440 ± 35,807 CD45+ cells), significantly higher
as compared to that of non-infected KO mice
(14,897 ± 4600 CD45+ cells) and infected WT
mice (30,995 ± 5542 CD45+ cells, Fig. 1F). Analysis
was done at 4 days post CVB3 infection as there
is onset of inflammation but no mortality is yet
observed in particular in the KO animals. Of note, the
absolute number of Ly6Chigh monocytes was signif-
icantly higher in the hearts of infected KO mice than
WT mice (46,014 ± 22,943 cells versus 11,072 ±
2651 cells), which was also true for the granulocyte
cells (4601 ± 2192 and 716 ± 186 cells for KO and
WT respectively, *p b 0.05, Fig. 1F).
Aggravated leukocyte recruitment in the
absence of SPARC was due to changes
in vascular permeability
As we found that lack of SPARC clearly resulted in
excessive immune infiltration due to viral exposure,
we wondered whether this would be the conse-
quence of SPARC either influencing the vasculature
or the leukocytes. SPARC not only co-stained with
the endothelium specific proteins CD31 and VCAM-
1 in CVB3-infected hearts, it also co-localized with
Wheat Germ Agglutinin (WGA), which is a lectin that
recognizes sialic acid and N-acetylglucosamine that
are present on glycoproteins within the extracellular
environment (Fig. 2A). SPARC did not co-localize
with CD45+ leukocytes indicating that the influence
of SPARC on immune cell recruitment during viral
myocarditis occurs on the level of the microvascu-
lature (Fig. 2A). The endothelial glycocalyx is largely
composed of carbohydrates found on proteoglycans
and glycoproteins and regulates vascular perme-
ability. Hence, the endothelial glycocalyx plays a
central role in modulating the influx of inflammatory
cells under homeostasis as well as pathophysiolog-
ical conditions [28–30]. To test whether SPARC
absence would induce alterations in vascular perme-
ability, two independent analyses were performed.
A qualitative analysis of systemically-injected micro-
spheres shows higher amounts of beads in the
cardiac environment of KO as compared to WT mice
(Fig. 2B). Likewise, a quantitative analysis of Evans
blue uptake revealed that KO mice have a more
permissive vasculature in the heart as compared to
Fig. 3. SPARC is needed for an intact endothelial glycocalyx hence impairs leukocyte recruitment. (A) Representative
image illustrating the experimental setup of the Cremaster experiments, adjusted images provided by the university of
Rochester. (B) Overview (right) and magnified (left) images of the microvasculature of the cremaster muscle illustrating
Texas Red-labelled Dextran40 (40 kDa) in the vasculature and its leakage in SPARCWT and KOmice untreated (control)
and in response to TNF-α stimulation. (C) The microvascular leakage of Texas red labelled Dextran40 was significantly
higher in SPARC KO as compared to WT mice (****p = 0.0001; Student t-test). Scale bar: 50 μm. Measurements were
performed in 25 and 26 vessels fromWT and KOmice respectively. (D) Electron microscopic imaging of cardiac capillaries
and arterioles demonstrating compromised endothelial glycocalyx in heart sections of SPARC KO mice (scale bar:
500 nm). (lu: Lumen, gly: glycocalyx, ec: endothelial cell). In vitro adhesive properties of leukocytes were no different under
static or (E) flow conditions between WT and KO (n = 3 per group for flow, n = 5 per group for static). (G) Intra-vital
microscopy of the cremaster muscle enabled the recording of leukocyte-endothelium interactions in SPARC WT and
KO microvessels at baseline and after stimulation with TNFα. (H) Adhesion efficacy, calculated by dividing the number
of adherent leukocytes by total rolling leukocytes, was significantly higher in SPARC KO animals compared to WT.
(I) Concordantly, cumulative frequency distribution of leukocyte velocities showed significant increased leukocyte
velocities in WT animals both before and after TNFα stimulation (One-way ANOVA, KO vs WT *p b 0.001; WT vs
WT + TNFα #p b 0.001; KO vs KO + TNFα ##p b 0.001; WT + TNFα vs KO + TNFα **p b 0.001). Measurements were
performed in N5 mice per group and 5 vessels per mouse, with ≥15 leukocyte velocities quantified per vessel.
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WT mice (Fig. 2C). During CVB3 infection this was
even more pronounced in the heart, and also true
for the lungs and liver (Fig. 2C). Finally, SPARC
was detected in a pull down of cardiac endothelial
cells using heparin-sepharose beads (Fig. 2D),
suggesting an interaction between SPARC and
heparan sulphates, one of the major glycocalyx com-
ponents [37,38].
Fig. 3 (legend on previous page)
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SPARC absence leads to altered vascular
permeability and leukocyte-endothelium
interactions by impeding glycocalyx integrity
As the endothelial glycocalyx regulates leukocyte
recruitment [31], the influence of SPARC on leuko-
cyte recruitment by modulating the structure lining
the endothelium was assessed by intra-vital micros-
copy in the cremaster muscle (Fig. 3A). This allows
the visualization of the microvessels and can be
used for the assessment of capillary permeability as
well as leukocyte adherence, rolling and velocity
[32]. The cremaster muscle was consequently
stimulated with TNF-α, a pro-inflammatory cytokine
central in the pathogenesis of viral myocarditis,
which activates the endothelium initiating degrada-
tion of the endothelial glycocalyx, enhancing leuko-
cyte adhesion and vascular permeability [33],
mimicking disease. Capillary leakiness as a conse-
quence of TNF-α stimulation was significantly higher
in SPARC KO as compared to WT mice, as
quantified by the extravasation of fluorescently
labelled dextran (p b 0.0001, Fig. 3B–C).
The malfunctioning endothelial barrier in SPARC
KO animals was potentially due to a damaged
endothelial glycocalyx, as observed with electron
microscopy using a specific protocol to preserve
the glycocalyx. SPARC KO mice had a severely
thinned or nearly absent glycocalyx in the capillaries
and arterioles in the heart, compared to the normal
glycocalyx in WT littermates (Fig. 3D). We next
wondered whether the decreased immune cell
recruitment to the myocardium of SPARC KO mice
was endothelial mediated or leukocyte mediated.
As no conditional SPARC KO mouse exists, in vitro
leukocyte adhesion assay under static conditions
and under conditions of flow were performed.
Freshly isolated leukocytes from KO and WT mice
adhered equally well to TNF-α-stimulated WT
cardiac microvascular endothelial cells under both
static and flow conditions (Fig. 3E, F). Given the
comparable endothelial glycocalyx in these cultured
primary endothelial cells [34], this experiment
suggested that not leukocyte derived SPARC but
endothelial glycocalyx derived SPARC was respon-
sible for the effect on cardiac inflammation. As the
endothelial glycocalyx is not only known to influence
vascular permeability but also plays a significant role
in regulating endothelium-leukocyte interactions
[35], we went back to the in vivo cremaster model
to investigate leukocyte adhesion and velocity
(Fig. 3F). In vivo, lack of SPARC resulted in a sig-
nificant increase of the adhesion efficacy - seen as
the percentage of adhering cells over total rolling
cells [36] – with an 8.6-fold increase in SPARC KO
mice versus a 4-fold increase in SPARC WT mice
after TNF-α stimulation (p b 0.05, Fig. 3G, H). In
agreement, leukocyte velocities were also signifi-
cantly reduced in SPARC KO mice as compared to
WT, both at baseline (*p b 0.001, Fig. 3I) and further
reduced after TNF-α stimulation (#/##/**p b 0.001,
Fig. 3I).
Administration of recombinant SPARC restored
the function of damaged glycocalyx
To show that SPARC's effect on the glycocalyx
was responsible for the observed increased inflam-
matory response, we tested whether glycocalyx
damage alone could phenocopy the SPARC KO
mice. Treatment of WT mice with hyaluronidase
(HAase) without consecutive CVB3 injection result-
ed in a severely damaged endothelial glycocalyx
as revealed via electron microscopy revealed, that
could be partially restored by a single injection of
recombinant SPARC (Fig. 4A). To see whether
HAase impeded glycocalyx-associated endothelial
barrier properties, and whether these could be
restored by recombinant SPARC administration, we
again went back to the cremaster model. Degradation
of the glycocalyx by injection of HAase resulted in the
expected increase in vascular leakiness (p N 0.0005,
Fig. 4B–C) and reduction of leukocyte velocities
(p b 0.001, Fig. 4D). Above all, leukocyte velocities
and microvascular leakiness were restored back to
baseline values in response to recombinant SPARC
administration that followed enzymatic degradation
of the endothelial surface layer (Fig. 4B–D). Finally,
we wondered whether lack of glycocalyx by HAase
treatment prior to CVB3 infection could phenocopy
SPARC KO mice. As anticipated, HAase treatment
significantly increased the cardiac infiltration 7 days
after viral infection (4 ± 1% in nontreated −HAase vs.
9 ± 2% in treated +HAase; p b 0.05, Fig. 4E–F)
without affecting mortality. Similarly to when SPARC
is absent, HAase treatment did not affect the viral
levels during the viremic phase (Fig. 4G).
Administration of recombinant SPARC reduced
cardiac inflammation and mortality in SPARC
KO mice
In order to explore the long-term effect of SPARC
loss on cardiac function after viral myocarditis,
SPARC KO and WT mice underwent echocardio-
graphic assessments at 4 days and 9 weeks after
viral infection. Concomitantly a group of KO and
WT mice received SPARC systemically for 5 weeks
and also underwent echocardiographic evaluation
(Table 1). Interestingly, dilated cardiomyopathy
started to present only in the KO mice at 9 weeks
post viral exposure (p = 0.02 and p = 0.04, for
fractional shortening FS and left ventricular systolic
dimension respectively, Table 1). This functional
deterioration observed in SPARC null mice could
unfortunately not be prevented by systemic SPARC
administration. However, SPARC administration did
significantly improve the survival of KO mice (14/15,
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p = 0.009, Fig. 5B–C) without having any benefit on
survival in their WT littermates. The improved survival
as a result of recombinant SPARC administration
in SPARC null mice, was reflected by the decrease
in cardiac inflammation (p b 0.05, Fig. 5D–E). In trying
to identify a possiblemortality cause for thesemicewe
hypothesised that aggravated cardiac inflammation
might lead to electrophysiological disturbances. Elec-
trocardiographic measurements were performed on
SPARC WT mice, SPARC KO mice either treated or
Fig. 4. Glycocalyx integrity is vital for limiting adverse inflammation. (A) Electron microscopic imaging of microvessels
showed clear glycocalyx degradation upon treatment with hyaluronidase (HAase). Recombinant SPARC treatment after
glycocalyx degradation restored glycocalyx integrity. Scale bar: 200 nm. (B–C) Representative images and quantification
of vascular leakiness. After degradation of hyaluronan (one of the major components of the endothelial glycocalyx) with
HAase the leakiness of Texas red labelled Dextran40 (40 kDa) increased, which could be restored by treatment with
recombinant SPARC (***p b 0.005; One-way ANOVA; scale bar: 50 μm). Measurements were performed in 25, 23 and 30
vessels from control, HAase and HAase + rSPARC treated animals respectively. (D) Significantly reduced leukocyte
velocities were found in mice injected with HAase, which again could be reversed by administration of recombinant
SPARC (Control vs HAase ***p = 0.0001, HAase vs HAase + SPARC #p = 0.01). (E) Representative images and
quantification (F) of leukocyte (CD45+ cell) staining of left ventricular myocardial sections showing an increase in
leukocyte infiltration in HAase treated mice compared to nontreated animals (*p b 0.05, Student t-test; N = 10, 8 for
−HAase and +HAase treatment respectively). Scale bar: 200 μm. (G) Prior to myocardial immune cell infiltration we did not
find a difference in viral presence in the myocardium of HAase treaded versus nontreated mice (n = 4).
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non-treated with recombinant SPARC. Unexpectedly,
while there were no significant differences in heart
rates between all animals, QTc times were reduced in
SPARC KO mice compared to WT yet could not be
restored upon recombinant SPARC administration
(**p b 0.05, Fig. 5F,G).
Discussion
Viral myocarditis is a clinical entity that is still very
difficult to diagnose let alone treat. Not only does it
result in sudden cardiac arrest it can eventually lead
to heart failure development. As the ECM is a vital
player regulating cardiac remodelling, we studied the
glycoprotein SPARC and showed that its absence
enhanced cardiac inflammation and mortality in the
CVB3 induced murine model of viral myocarditis.
Knowing the importance of the endothelium in
recruiting leukocytes and the clear immunohisto-
chemical localization of SPARC on the endothelium,
our interest was drawn to the endothelial glycocalyx.
Whilst the endothelial glycocalyx is comprised of
similar building blocks found in the ECM and is
known for regulating leukocyte recruitment and
vascular permeability, we show for the first time
that extracellular matrix protein SPARC is an
essential regulator of microvascular barrier function.
Lack of SPARC results in a loss of glycocalyx
integrity and consecutive barrier function as leuko-
cyte adhesion and vascular permeability increase
when the endothelial glycocalyx is compromised,
either by lack of SPARC or by enzymatic degrada-
tion of one of its major components (hyaluronan).
These alterations in glycocalyx integrity result in
increased cardiac inflammation and mortality during
viral myocarditis. Most importantly, administration
of recombinant SPARC was able to reverse the
adverse effects of the glycocalyx damage, and
restore the associated glycocalyx functional impair-
ment resulting in reduced vascular leakage.
The composition of the glycocalyx is controlled
by multiple factors and requires a timely balance
between synthesis and degradation. Though little is
known about the regulation of the glycocalyx, there
is growing appreciation of its importance in organ
homeostasis and disease. Numerous studies show
that changes in shear stress, hypoxia, hyperglyce-
mia, oxidized LDL or inflammation can induce
glycocalyx perturbation and hence contribute to the
vascular dysfunction observed in sepsis [39], acute
respiratory syndrome [40], albuminuria [41], athero-
sclerosis [42], diabetes [43] and obesity [44].
Changes in myocardial glycocalyx have been
observed in cardiac pathologies such as ischemia-
reperfusion injury [45], excessive oedema [46] and
cardiogenic shock [47]. Furthermore, a review about
the cardiovascular manifestations of dengue fever,
suggested that alterations in glycocalyx might
contribute to the capillary leakiness observed during
infection and contribute to the myocarditis observed
[48]. However this study is the first to implicate
glycocalyx perturbations to the pathophysiology of
viral myocarditis.
Whilst the need to have SPARC for proper
endothelial glycocalyx composition has not been
identified before, in vitro studies have shown that
SPARC can bind to albumin [49], which itself can
Table 1
. Cardiac function and mortality in SPARC WT and KO animals during viral myocarditis.
Time point Day 4
WT KO WT + S KO + S
Survival (%) 14/14100% 21/21100% 12/12100% 15/15100%
LVIDd (mm) 3.7 ± 0.5 3.7 ± 0.3 3.6 ± 0.2 3.5 ± 0.2
LVIDs (mm) 2.7 ± 0.5 2.4 ± 0.3 2.5 ± 0.4 2.3 ± 0.3
FS (%) 27.5 ± 6.4 34.9 ± 4.9* 30.4 ± 10.2 34.7 ± 8.0
HR (bpm) 538 ± 36 495 ± 40 542 ± 47 503 ± 54
LVIDd Left ventricular internal diameter end diastole; LVIDs Left ventricular internal diameter end systole; FS Fractional Shortening; HR
Heart Rate
+S refers to treatment with recombinant SPARC
*WT vs KO p b 0.05
Time point Week 9
WT KO WT + S KO + S
Survival (%) 11/14 78.6% 9/21 42.9% 9/12 75.0% 14/15 93.3%
LVIDd (mm) 3.9 ± 0.5 3.8 ± 0.3 3.7 ± 0.3 3.8 ± 0.4
LVIDs (mm) 2.7 ± 0.6 2.8 ± 0.5# 2.7 ± 0.4 2.7 ± 0.4
FS (%) 30.3 ± 9.5 25.8 ± 7.1# 29.3 ± 7.7 29.7 ± 6.8
HR (bpm) 475 ± 103 428 ± 48 552 ± 51.8 432 ± 22.4
#KO day 4 vs KO week 9 p b 0.05.
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regulate glycocalyx integrity [41]. The immunomod-
ulatory role of SPARC in previous studies using in
vitro experiments, was ascribed to leukocyte-derived
SPARC facilitating leukocyte transmigration across
an endothelial monolayer [50], and to endothelial
cytoskeleton rearrangements induced by SPARC
treatment [51]. However, the role of SPARC on
inflammation has been bi-directional in current liter-
ature as few studies elude to either a pro- or anti-
inflammatory effect of SPARC. In a murine-model
for pulmonary fibrosis SPARC is identified as anti-
inflammatory [52], whereas it clearly enhances
leukocyte recruitment in a murine peritonitis model
[53]. The mechanism whereby SPARC affects in-
flammation in these models by either influencing
TGFβ activity or interacting with VCAM-1 [54], fail to
comprehensively explain these contradictory find-
ings. Here, the importance of SPARC in endothelial
glycocalyx composition and function may clarify its
bi-directional role on inflammation. Indeed, differen-
tial presence of SPARC in the endothelial surface
layer of different vascular beds may explain the
seemingly opposing effect SPARC has on inflam-
mation in different tissues and disease models.
Although it is well established that every vascular
bed has very unique structural and functional char-
acteristics [55,56], whether these unique endothelial
characteristics will lead to specific and distinctive
glycocalyx composition has unfortunately not been
demonstrated yet, mainly due to technical limita-
tions. Nevertheless, we do know that the endothelial
glycocalyx consist of numerous complex soluble and
insoluble glycoproteins, proteoglycans and glycosa-
minoglycan's mostly produced by the endothelial
cells. Further, the thickness of this structure can vary
enormously [14] throughout the vasculature. We
therefore strongly believe that glycocalyx composi-
tion can differ between various vascular beds as a
consequence of unique structural and functional
characteristics of the endothelium; hence differential
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Fig. 5. Recombinant SPARC administration reduces mortality and alleviates heart failure development. (A) Cardiac
function significantly deteriorated in SPARC KO mice 9 weeks after viral exposure as compared to WT (*p b 0.05).
Administration of recombinant SPARC seemed to improve cardiac function in viral myocarditis. (B,C) Survival curve
showing that administration of recombinant SPARC reduces the mortality in SPARC KO mice in response to viral
exposure. (*p b 0.01 using Mantel-Cox method, N = 14, 12, 15 and 17 in WT, WT + rSPARC, KO and KO + rSPARC)
(D,E) Recombinant SPARCadministrated blunted the increased infiltration of immune cells in SPARCKOmice 7 days after
CVB3 administration. (p b 0.05; One-way ANOVA) (F,G) Lack of SPARC reduced the QTc time on electrocardiographic
measurements significantly in KO mice compared to WT while not affecting the heart rate. (**p b 0.01; One-way ANOVA).
Fractional shortening and inflammation were measured in 11, 9, 9 and 14 WT, WT + rSPARC, KO and KO + rSPARC
animals respectively. Scale bar: 50 μm.
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SPARC presence in the glycocalyx could affect
inflammation differently in different tissues and in
different diseases, also explaining the opposing
effect found using in vitro models.
Glycoproteins have been suggested as important
“backbone” molecules for the glycocalyx structure
[14]. It is possible that the reduced endothelial barrier
properties in SPARC KO mice are a consequence of
a lack of proper glycocalyx anchoring rather than an
impaired glycocalyx synthesis. Interestingly, there
have been studies showing successful restoration of
the shedded endothelial glycocalyx after administra-
tion of heparan sulphate, one of the major compo-
nents of the glycocalyx in vitro [57]. Considering our
heparan sulphate pull down showed a clear binding
of SPARC to this prevalent glycosaminoglycan, and
the clear improvement of endothelial barrier proper-
ties after administration of recombinant SPARC,
we considered the possible importance of SPARC-
heparan sulphate interaction in glycocalyx regener-
ation as proposed by Ebong et al. [57]. However,
the exact mechanism via which SPARC affects the
glycocalyx needs to be further elaborated.
During myocarditis, systemic SPARC administra-
tion rescued KO mice survival though it did not affect
the amount of myocyte cell injury as measured
by troponin levels at day 7 post viral exposure
(Supplementary Fig. 1D). Furthermore, inflammatory
dilated cardiomyopathy develops progressively over
time in CVB3 induced viral myocarditis in mice and
is prevalent as a consequence of cardiomyocyte
loss and adverse cardiac inflammation [58]. Similarly
to the clinical scenario, dilated cardiomyopathy was
not present in all CVB3 infected mice at 9 weeks.
However, we did observe dilated cardiomyopathy
mainly in KO mice and less in WT mice. Moreover,
administration of recombinant SPARC improved
cardiac function in SPARC KO mice. These data
are in line with other studies showing that limiting the
cardiac infiltration during the acute phase improves
the long-term function [59].
Where administration of recombinant SPARC
clearly improved glycocalyx integrity and consecu-
tive inflammation and mortality, the exact cause
of death in SPARC KO mice still remains elusive.
Electrocardiographic analysis did reveal a shorten-
ing of the QTc time in SPARC KOmice as compared
to WT, which has been correlated with increased
mortality as a consequence of cardiac arrhythmias
[60]. Interestingly, it has been suggested that glyco-
sylated proteins comprising the endothelial glycocalyx
are vital mechanosensors that initiate the production
of nitric oxide (NO) resulting in coronary artery dilation
and suppression of platelet aggregation [61–65]. As
coronary flow can be reduced in myocarditis mimick-
ing acute coronary syndrome [66], lack of proper
mechanosensing may therefore contribute to the
functional deterioration and, combinedwith increasing
inflammation, eventual lead to arrhythmias and death
in SPARC KO mice. However, the present study
concentrated on the effects of SPARC at the level of
endothelial glycocalyx and can thus not rule out
potential additive/negative effects of SPARC at the
level of the single cardiac myocyte.
Collectively, our data identify SPARC as crucial
component of the endothelial barrier and thus
prevents pathological cardiac inflammation and mor-
tality. SPARC may therefore represent a novel ther-
apeutic tool to repair or maintain endothelial barrier
integrity in cardiac disease.
Material and methods
Animals
C57Bl6/J maleSPARC-KO (backcrossed 10 times)
and WT C57Bl6/J mice (Harlan, the Netherlands)
between 10 and 18 weeks of age were used. Mice
were maintained in specific pathogen-free facilities
at Maastricht or Leuven University. The Animal Care
and Use Committee of the University of Maastricht
and Leuven approved all described study protocols,
according to the Dutch (2012/031) and Belgian law
(067/2008, 043/2013) and all animal procedures were
performed conform to the guidelines from Directive
2010/63/EU of the European Parliament.
Murine CVB3 induced viral myocarditis model
Eight to 12-week old inbred C57Bl6/J SPARC-KO
and WT mice were inoculated intra-peritoneal (i.p.)
with 1 × 107 cell culture 50% infective dose (CCID50)
of CVB3 (Nancy Strain) and cardiac immune cell
infiltration was measured 7 days later. For long-term
administration (5 weeks) mice received SPARC via
osmotic minipump. Troponin was measured using
a high sensitivity ELISA 7 days after viral exposure
(Roche Diagnostics). Mice received hyaluronidase
(iv 70 U) [67] 1 h prior to CVB3. All animals were
anesthetized with an intra-peritoneal injection of
xylazine (10 mg/kg) and ketamine (100 mg/kg) and
sacrificed by cervical dislocation. Male mice were
used for all experiments except for the long-term
9-weeks viral myocarditis experiment where both
Female WT and KO mice were included in equal
numbers.
Mouse cremaster preparation and
intravital microscopy
Mice were anesthetized and the exposed muscle
was positioned on a clear Silicon pedestal and
longitudinally incised from the apex to the inguinal
canal with minimal disruption of the vascular supply.
The stage of the intravital microscope (Olympus
BHM) was coupled to a cooled intensified CCD video
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camera (GenIV ICCD, Princeton Instruments). Cre-
mastermuscle capillaries were examinedwith a water
immersion objective lens (Olympus; LUMPlanFL, NA
0.9). The muscle was continuously (5 ml/min) super-
fused at 37 °C with a bicarbonate-buffered physiolog-
ical salt solution (PSS). Texas Red labelled 40 kDa
dextrans (Dex-40; Invitrogen) were intravenously
injected at 10 mg/ml in PBS. Cremaster capillaries
of 30–50 μm were chosen for examination from
different microscopic field, and recorded on videotape
using trans and epi-illumination. After baseline re-
cordings were made (15–20 min) TNF-α (2 ng/ml;
Peprotech) was dropped on the Cremaster muscle for
5 min. Recordings of the same capillaries were made
at baseline, after 60 and 120 min. 0.1 ml recombinant
SPARC (15 μg/kg, R and D systems) was injected
i.v. at a concentration of 0,15 mg/kg prior to TNF-α
stimulation. 0.1 ml (35 U) of hyaluronidase was
injected after the equilibration period and SPARC
was injected 10 min after the injection of hyaluroni-
dase. Rolling leukocytes were measured by counting
the visible passing leukocytes for 60 s. Counting
cells that adhered to the vessel wall for ≥30 s and did
not move more than their own diameter in distance
across the vessel wall during this period qualified
as adherent leukocytes. Adhesion efficacy could be
calculated by dividing the number of adherent leuko-
cytes by the total number of rolling leukocytes.
Leukocyte velocities were determined by measuring
the time it took individual cells to travel 150 μm in
distance. Only cells that were visible during the entire
course were include. Hokawo 2.5 Wasabi Software
and Image J 1.48v were used for post-hoc data
analysis.
Cardiac fractionation and flow cytometry
Peripheral blood and the cardiac immune cell
fractionswere analyzed using aCantoII flow cytometer
(Becton Dickenson (BD), San Diego, CA). Cells were
first incubated with anti-CD16/32 (eBioscience, San
Diego, CA, #14-0161-85,1:100) to block Fc receptor
binding. CD45+ leukocytes subpopulations were
identified (Biolegend, #103129, 1:100) and defined
as follows: T lymphocytes (CD3+,eBioscience, # 57-
0033-80,1:100), B lymphocytes (B220+,BD # 561226,
1:50), Granulocytes (CD11b+, BD# 552850 1:2000,
Ly6G+, BD# 560600, 1:100), Monocytes (CD11b+,
F4/80-, Biolegend #123116, 1:100, Ly6C+, Miltenyi #
130-093-134, 1:20). Absolute counts for cardiac and
blood samples were determined with BD Truecount™
tubes according to the manufacturer's instructions.
Adhesion assay
Mouse endothelial cells (SVEC, simian virus 40-
transformed mouse microvascular endothelial cells)
were seeded on μ-slideVI0.4 (Ibidi, Planegg,Germany)
and then stimulated with 10 ng/ml TNF-α for 24 h.
700 μL of blood was isolate from either wild-type or
knockout mice as indicated. The red blood cells were
lysed to produce a mixed leukocyte population and
stained with the intracellular fluorescent cell label
carboxyfluorescein N-hydroxysuccinimidyl ester (or
CFSE). Endothelial cells were then exposed to these
leukocytes under flow. To that end, the white blood
cells from one mouse were added to at a concen-
tration of 106/mL. The flow rate was set to produce
1.25 dyne/cm2. Endothelial cells were exposed to
white blood cells to flow for a period of 4 h. The
system was flushed with PBS, and then the slides
were transferred to a confocal microscope. Three
images at random locations, chosen based on the
transmitted light, were taken of the fluorescently
labelled white blood cells. The average number of
adhered cells per unit area was calculated.
Static adhesion assays where performed as
follows: Spleens of SPARC WT and KO mice were
removed and mashed over a 40 μm mesh. Cell
suspensions were then incubated with CD45+ beads
(Miltenyi Biotech, Germany) according to the man-
ufacturer's instructions in order to isolate the
monocytes. Isolated cells were labelled with CFSE
(Molecular Probes, Invitrogen) and then placed on
top of TNF-α (10 ng/ml) stimulated mouse endothe-
lial cells (SVEC, simian virus 40-transformed mouse
microvascular endothelial cells) and allowed to
adhere for 2 h at 37 °C. Non-adherent cells were
washed off and the remaining adhered cells quan-
tified with a Victor 2 microplate reader (Perkin-Elmer,
USA).
Staining and Immunohistochemistry
4 μm thick sections were stained with CD45 (BD
Pharmingen, catalog no. 553076, 1:100) for deter-
mining the amount of inflammation. Immunofluores-
cence of paraffin sections was performed according
to protocol using antibodies against CD45 (BD
Pharmingen, catalog no. 553076, 1:100), CD31 (BD
Pharmingen, catalog no. 557355, 1:500), VCAM-1
(BD Pharmingen, catalog no. 553330, 1:50) and
SPARC (R&D, catalog no. AF942, 1:100). Images
were acquired using Leica Qwin image processing
software (Leica, Germany).
Electron microscopy
Hearts were fixed by perfusing 5-10 ml of Glutar-
aldehyde 2,5%, Saccharose 12%, Na-cacodylate
3 H2O 0,4 M pH 7,3, lanthanum 4% pH 7,4 after
which they were sectioned into small cubes that
were fixed for another 2 h. Samples were dehy-
drated in graded series of ethanol and embedded in
Araldite (CY-212; Serva). Ultrathin sections were
counterstained with uranium acetate and lead citrate
prior to examination in a Philips CM100 electron
microscope.
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Real time PCR
Real-time reverse transcriptase–polymerase chain
reaction (RT-PCR) analysis was performed (Bio-Rad,
Maastricht, Netherlands) to determine transcript with
the following primers; U6 (FWDCGC-TTC-GGC-AGC-
ACA-TAT-AC, BWD TTC-ACG-AAT-TTG-CGT-GTC-
AT), MDA5 (FWD GCC-TGG-AAC-GTA-GAC-GAC-
AT, BWD TTG-GGC-CAC-TTC-CAT-TTG-GT), RIG-1
(FWD AGA-CGG-TTC-ACC-GCA-TAC-AG, BWD
AAG-CGT-CTC-CAA-GGA-CAG-TG), CVB3 (FWD
ACG-AAT-CCC-AGT-GTG-TTT-TGG, BWD TGC-
TCA-AAA-ACG-GTA-TGG-ACA-T), TLR3 (FWD
AGC-ATC-AAA-AGA-AGC-CGA-AA, BWD CTT-
GCT-GAA-CTG-CGT-GAT-GT). Data were acquired
and analyzed IQ5 software (Bio-Rad, Maastricht,
Netherlands).
Vascular permeability assay
Vascular permeability experiments with Evans Blue
dye were performed in heart, lung, liver, spleen and
skin as previously described [68,69]. Bead extrava-
sation was done as follows; a 1:10 dilution of red
fluorescent microbeads (Invitrogen, Fluospheres)
was tail vein injected. The beads were allowed to
circulate for 2 min, before intracardiac perfusion of 1%
PFA for 15 min. Heart were then dissected, further
fixed for 1 h in 1% PFA, cryo-embedded, sectioned
and then immunostained for VE-Cadherin (R&D
Systems). Sections were imaged using z-sectioning
on a confocal Zeiss LSM700.
Echocardiographic and ECG recordings
Animals were anesthetized and placed in a supine
position on a heating pad to keep the internal body
temperature between 37.5 and 37.7 °C by using a
rectal probe. Standard views were obtained in 2-D as
well as M-mode by transthoracic echocardiography
using a 12 MHz probe (Hewlett Packard, Amsterdam,
theNetherlands) onaVisual Sonics echocardiograph.
ECG signals were measured in SPARC KO and
WTmice and QTc times were assessed for individual
heartbeats.
Statistical analysis
Results represent the mean ± SEM unless indi-
cated otherwise. For murine studies, D'Agostino and
Pearson's omnibus normality test was performed.
Statistical significance was determined by unpaired
Student's t-test or ANOVA when data were normally
distributed. Wilcoxon, Mann-Whitney or Kruskal-
Wallis test was used for non-parametric data as
indicated. Gehan-Breslow-Wilcoxon or Mantel-Cox
test was used for survival analysis. Statistical anal-
yses were performed with Prism GraphPad software
v5.0.
Supplementary data to this article can be found
online at https://doi.org/10.1016/j.matbio.2018.04.015.
Acknowledgements & funding
This work was supported by the European
Commission grant N° 602904 (FIBROTARGETS),
N° 261409 (MEDIA), the NWO Vidi (91796338) and
the CVON 2011 (CVON2011-11) (ARENA).
Conflict of interest
The authors have nothing to disclose.
Received 8 February 2018;
Received in revised form 29 April 2018;
Accepted 30 April 2018
Available online 3 May 2018
Keywords:
SPARC;
Endothelial glycocalyx;
Viral myocarditis;
Extracellular matrix;
Inflammation
†Contributed equally.
References
[1] H.T. Aretz, M.E. Billingham, W.D. Edwards, S.M. Factor, J.T.
Fallon, J.J. Fenoglio Jr., E.G. Olsen, F.J. Schoen, Myocar-
ditis. A histopathologic definition and classification, Am J
Cardiovasc Pathol 1 (1) (1987) 3–14.
[2] S. Sakakibara, S. Konno, Endomyocardial biopsy, Jpn. Heart
J. 3 (1962) 537–543.
[5] E. Funseth, U. Lindh, L. Wesslen, G. Friman, N.G. Ilback,
Trace element changes in the myocardium during coxsack-
ievirus B3 myocarditis in the mouse, Biol. Trace Elem. Res.
76 (2) (2000) 149–160.
[6] S. Sagar, P.P. Liu, L.T. Cooper Jr., Myocarditis, Lancet 379
(9817) (2012) 738–747.
[7] M.J. Sole, P. Liu, Viral myocarditis: a paradigm for
understanding the pathogenesis and treatment of dilated
cardiomyopathy, J. Am. Coll. Cardiol. 22 (4 Suppl A) (1993)
99A–105A.
[8] A. Naba, K.R. Clauser, H. Ding, C.A. Whittaker, S.A. Carr, R.
O. Hynes, The extracellular matrix: tools and insights for the
“omics” era, Matrix Biol. 49 (2016) 10–24.
[9] J. Barallobre-Barreiro, A. Didangelos, F.A. Schoendube, I.
Drozdov, X. Yin, M. Fernandez-Caggiano, P. Willeit, V.O.
Puntmann, G. Aldama-Lopez, A.M. Shah, N. Domenech, M.
Mayr, Proteomics analysis of cardiac extracellular matrix
remodeling in a porcine model of ischemia/reperfusion injury,
Circulation 125 (6) (2012) 789–802.
32 SPARC preserves endothelial glycocalyx integrity
[10] M. Rienks, A.P. Papageorgiou, N.G. Frangogiannis, S.
Heymans, Myocardial extracellular matrix: an ever-changing
and diverse entity, Circ. Res. 114 (5) (2014) 872–888.
[11] S. Van Linthout, C. Tschope, Inflammation - cause or
consequence of heart failure or both? Curr Heart Fail Rep
14 (4) (2017) 251–265.
[12] M. Rienks, A. Papageorgiou, K. Wouters, W. Verhesen, R.V.
Leeuwen, P. Carai, G. Summer, D.Westermann, S. Heymans,
A novel 72-kDa leukocyte-derived osteoglycin enhances
the activation of toll-like receptor 4 and exacerbates cardiac
inflammation during viral myocarditis, Cell. Mol. Life Sci. 74 (8)
(2017) 1511–1525.
[13] S.Deckx,W.Heggermont, P.Carai,M. Rienks, T.Dresselaers,
U. Himmelreich, R. van Leeuwen, W. Lommen, J. van der
Velden,A.Gonzalez, J.Diez,A.P.Papageorgiou,S.Heymans,
Osteoglycin prevents the development of age-related diastolic
dysfunction during pressure overload by reducing cardiac
fibrosis and inflammation, Matrix Biol. 66 (2018) 110–124.
[14] S. Reitsma, D.W. Slaaf, H. Vink, M.A. van Zandvoort, M.G.
oude Egbrink, The endothelial glycocalyx: composition, func-
tions, and visualization, PflugersArch. 454 (3) (2007) 345–359.
[15] X. Zhang, D. Sun, J.W. Song, J. Zullo, M. Lipphardt, L.
Coneh-Gould, M.S. Goligorsky, Endothelial cell dysfunction
and glycocalyx - a vicious circle, Matrix Biol. (2018) [Epub
ahead of print].
[16] M.W. Schellings, D. Vanhoutte, M. Swinnen, J.P. Cleutjens, J.
Debets, R.E. van Leeuwen, J. d'Hooge, F. Van de Werf, P.
Carmeliet, Y.M. Pinto, E.H. Sage, S. Heymans, Absence of
SPARC results in increased cardiac rupture and dysfunction after
acute myocardial infarction, J. Exp. Med. 206 (1) (2009) 113–123.
[17] A.D. Bradshaw, C.F. Baicu, T.J. Rentz, A.O. Van Laer, J.
Boggs, J.M. Lacy, M.R. Zile, Pressure overload-induced
alterations in fibrillar collagen content and myocardial
diastolic function: role of secreted protein acidic and rich in
cysteine (SPARC) in post-synthetic procollagen processing,
Circulation 119 (2) (2009) 269–280.
[18] A.D. Bradshaw, C.F. Baicu, T.J. Rentz, A.O. Van Laer, D.D.
Bonnema, M.R. Zile, Age-dependent alterations in fibrillar
collagen content and myocardial diastolic function: role of
SPARC in post-synthetic procollagen processing, Am. J.
Physiol. Heart Circ. Physiol. 298 (2) (2010) H614–22.
[19] A. Francki, A.D. Bradshaw, J.A. Bassuk, C.C. Howe, W.G.
Couser, E.H. Sage, SPARC regulates the expression of
collagen type I and transforming growth factor-beta1 in
mesangial cells, J. Biol. Chem. 274 (45) (1999) 32145–32152.
[20] N. Said, H.F. Frierson, M. Sanchez-Carbayo, R.A. Brekken,
D. Theodorescu, Loss of SPARC in bladder cancer
enhances carcinogenesis and progression, J. Clin. Invest.
123 (2) (2013) 751–766.
[21] N. Said, H.F. Frierson Jr., D. Chernauskas, M. Conaway, K.
Motamed, D. Theodorescu, The role of SPARC in the
TRAMP model of prostate carcinogenesis and progression,
Oncogene 28 (39) (2009) 3487–3498.
[22] E.M. Rosset, A.D. Bradshaw, SPARC/osteonectin in miner-
alized tissue, Matrix Biol. 52–54 (2016) 78–87.
[23] M.J. Reed, A.D. Bradshaw, M. Shaw, E. Sadoun, N. Han, N.
Ferara, S. Funk, P. Puolakkainen, E.H. Sage, Enhanced
angiogenesis characteristic of SPARC-null mice disappears
with age, J. Cell. Physiol. 204 (3) (2005) 800–807.
[24] L. Vaughan, R. Marley, S. Miellet, P.S. Hartley, The impact of
SPARC on age-related cardiac dysfunction and fibrosis in
Drosophila, Exp. Gerontol. (2017) [Epub ahead of print].
[25] L.E. de Castro Bras, H. Toba, C.F. Baicu, M.R. Zile, S.T.
Weintraub, M.L. Lindsey, A.D. Bradshaw, Age and SPARC
change the extracellular matrix composition of the left
ventricle, Biomed. Res. Int. (2014) 810562.
[26] S.A. Arnold, L.B. Rivera, A.F. Miller, J.G. Carbon, S.P. Dineen,
Y. Xie, D.H. Castrillon, E.H. Sage, P. Puolakkainen, A.D.
Bradshaw, R.A. Brekken, Lack of host SPARC enhances
vascular function and tumor spread in an orthotopic murine
model of pancreatic carcinoma, Dis. Model. Mech. 3 (1–2)
(2010) 57–72.
[27] R.A. Brekken, E.H. Sage, SPARC, a matricellular protein:
at the crossroads of cell-matrix communication, Matrix Biol.
19 (8) (2001) 816–827.
[28] S. Weinbaum, J.M. Tarbell, E.R. Damiano, The structure and
function of the endothelial glycocalyx layer, Annu. Rev.
Biomed. Eng. 9 (2007) 121–167.
[29] H. Kolarova, B. Ambruzova, L. Svihalkova Sindlerova, A.
Klinke, L. Kubala, Modulation of endothelial glycocalyx
structure under inflammatory conditions, Mediat. Inflamm.
2014 (2014) 694312.
[30] B.F. Becker, D. Chappell, D. Bruegger, T. Annecke, M. Jacob,
Therapeutic strategies targeting the endothelial glycocalyx:
acute deficits, but great potential, Cardiovasc. Res. 87 (2)
(2010) 300–310.
[31] E.P.Schmidt, Y.Yang,W.J. Janssen,A.Gandjeva,M.J.Perez,
L. Barthel, R.L. Zemans, J.C. Bowman, D.E. Koyanagi, Z.X.
Yunt, L.P. Smith, S.S. Cheng, K.H. Overdier, K.R. Thompson,
M.W. Geraci, I.S. Douglas, D.B. Pearse, R.M. Tuder,
The pulmonary endothelial glycocalyx regulates neutrophil
adhesion and lung injury during experimental sepsis, Nat. Med.
18 (8) (2012) 1217–1223.
[32] P. Bagher, S.S. Segal, The mouse cremaster muscle
preparation for intravital imaging of the microcirculation,
J. Vis. Exp. (52) (2011).
[33] C.B. Henry, B.R. Duling, TNF-alpha increases entry of
macromolecules into luminal endothelial cell glycocalyx,
Am. J. Physiol. Heart Circ. Physiol. 279 (6) (2000) H2815–23.
[34] E.E. Ebong, F.P. Macaluso, D.C. Spray, J.M. Tarbell,
Imaging the endothelial glycocalyx in vitro by rapid freez-
ing/freeze substitution transmission electron microscopy,
Arterioscler. Thromb. Vasc. Biol. 31 (8) (2011) 1908–1915.
[35] U. Schott, C. Solomon, D. Fries, P. Bentzer, The endothelial
glycocalyx and its disruption, protection and regeneration: a
narrative review, Scand. J. Trauma Resusc. Emerg. Med. 24
(2016) 48.
[36] S.M. Jakob, R. Pick, D. Brechtefeld, C. Nussbaum, F. Kiefer,
M. Sperandio, B. Walzog, Hematopoietic progenitor kinase 1
(HPK1) is required for LFA-1-mediated neutrophil recruitment
during the acute inflammatory response, Blood 121 (20)
(2013) 4184–4194.
[37] N.S. Ihrcke, L.E. Wrenshall, B.J. Lindman, J.L. Platt, Role of
heparan sulfate in immune system-blood vessel interactions,
Immunol. Today 14 (10) (1993) 500–505.
[38] A.R. Pries, T.W. Secomb, P. Gaehtgens, The endothelial
surface layer, Pflugers Arch. 440 (5) (2000) 653–666.
[39] M. Henrich, M. Gruss, M.A. Weigand, Sepsis-induced
degradation of endothelial glycocalix, ScientificWorldJournal
10 (2010) 917–923.
[40] D. Mehta, K. Ravindran, W.M. Kuebler, Novel regulators of
endothelial barrier function, Am. J. Physiol. Lung Cell. Mol.
Physiol. 307 (12) (2014) L924–35.
[41] A.H. Salmon, J.K. Ferguson, J.L. Burford, H. Gevorgyan,
D. Nakano, S.J. Harper, D.O. Bates, J. Peti-Peterdi, Loss
of the endothelial glycocalyx links albuminuria and
vascular dysfunction, J. Am. Soc. Nephrol. 23 (8) (2012)
1339–1350.
33SPARC preserves endothelial glycocalyx integrity
[42] A. Koo, C.F. Dewey Jr., G. Garcia-Cardena, Hemodynamic
shear stress characteristic of atherosclerosis-resistant re-
gions promotes glycocalyx formation in cultured endothelial
cells, Am. J. Physiol. Cell Physiol. 304 (2) (2013) C137–46.
[43] R.M. Perrin, S.J. Harper, D.O. Bates, A role for the
endothelial glycocalyx in regulating microvascular perme-
ability in diabetes mellitus, Cell Biochem. Biophys. 49 (2)
(2007) 65–72.
[44] B.J. Eskens, T.M. Leurgans, H. Vink, J.W. Vanteeffelen,
Early impairment of skeletal muscle endothelial glycocalyx
barrier properties in diet-induced obesity in mice, Phys. Rep.
2 (1) (2014), e00194. .
[45] I. Rubio-Gayosso, S.H. Platts, B.R. Duling, Reactive oxygen
species mediate modification of glycocalyx during ischemia-
reperfusion injury, Am. J. Physiol. Heart Circ. Physiol. 290 (6)
(2006) H2247–56.
[46] B.M. van den Berg, H. Vink, J.A. Spaan, The endothelial
glycocalyx protects against myocardial edema, Circ. Res. 92
(6) (2003) 592–594.
[47] C. Jung, G. Fuernau, P. Muench, S. Desch, I. Eitel, G.
Schuler, V. Adams, H.R. Figulla, H. Thiele, Impairment of the
endothelial glycocalyx in cardiogenic shock and its prognos-
tic relevance, Shock 43 (5) (2015) 450–455.
[48] S. Yacoub, H. Wertheim, C.P. Simmons, G. Screaton, B.
Wills, Cardiovascular manifestations of the emerging dengue
pandemic, Nat. Rev. Cardiol. 11 (6) (2014) 335–345.
[49] J.E. Schnitzer, P. Oh, Antibodies to SPARC inhibit albumin
binding to SPARC, gp60, and microvascular endothelium,
Am. J. Phys. 263 (6 Pt 2) (1992) H1872–9.
[50] K.A. Kelly, J.R. Allport, A.M. Yu, S. Sinh, E.H. Sage, R.E.
Gerszten, R. Weissleder, SPARC is a VCAM-1 counter-
ligand that mediates leukocyte transmigration, J. Leukoc.
Biol. 81 (3) (2007) 748–756.
[51] S.E. Goldblum, X. Ding, S.E. Funk, E.H. Sage, SPARC
(secreted protein acidic and rich in cysteine) regulates
endothelial cell shape and barrier function, Proc. Natl.
Acad. Sci. U. S. A. 91 (8) (1994) 3448–3452.
[52] S. Sangaletti, C. Tripodo, B. Cappetti, P. Casalini, C.
Chiodoni, S. Piconese, A. Santangelo, M. Parenza, I. Arioli,
S. Miotti, M.P. Colombo, SPARC oppositely regulates
inflammation and fibrosis in bleomycin-induced lung dam-
age, Am. J. Pathol. 179 (6) (2011) 3000–3010.
[53] K.A. Kelly, J.R. Allport, A.M. Yu, S. Sinh, E.H. Sage, R.E.
Gerszten, R. Weissleder, SPARC is a VCAM-1 counter-
ligand that mediates leukocyte transmigration, J. Leukoc.
Biol. 81 (3) (2007) 748–756.
[54] J. Trombetta-Esilva, A.D. Bradshaw, The function of SPARC
as a mediator of fibrosis, Open Rheumatol. J. 6 (2012)
146–155.
[55] W.C. Aird, Phenotypic heterogeneity of the endothelium: II.
Representative vascular beds, Circ. Res. 100 (2) (2007)
174–190.
[56] W.C. Aird, Phenotypic heterogeneity of the endothelium: I.
Structure, function, and mechanisms, Circ. Res. 100 (2)
(2007) 158–173.
[57] S.A. Mensah, M.J. Cheng, H. Homayoni, B.D. Plouffe, A.J.
Coury, E.E. Ebong, Regeneration of glycocalyx by heparan
sulfate and sphingosine 1-phosphate restores inter-endothelial
communication, PLoS One 12 (10) (2017), e0186116.
[58] P.M. Becher, F. Gotzhein, K. Klingel, F. Escher, S.
Blankenberg, D. Westermann, D. Lindner, Cardiac function
remains impaired despite reversible cardiac remodeling after
acute experimental viral myocarditis, J. Immunol. Res. 2017
(2017), 6590609.
[59] M.F. Corsten, A. Papageorgiou, W. Verhesen, P. Carai, M.
Lindow, S. Obad, G. Summer, S.L. Coort, M. Hazebroek, R.
van Leeuwen, M.J. Gijbels, E. Wijnands, E.A. Biessen, M.P.
De Winther, F.R. Stassen, P. Carmeliet, S. Kauppinen, B.
Schroen, S. Heymans, MicroRNA profiling identifies
MicroRNA-155 as an adverse mediator of cardiac injury
and dysfunction during acute viral myocarditis, Circ. Res. 111
(4) (August 3, 2012).
[60] Y. Zhang, W.S. Post, D. Dalal, E. Blasco-Colmenares, G.F.
Tomaselli, E. Guallar, QT-interval duration and mortality rate:
results from the Third National Health and Nutrition Exam-
ination Survey, Arch. Intern. Med. 171 (19) (2011)
1727–1733.
[61] R. Rubio, G. Ceballos, Role of the endothelial glycocalyx in
dromotropic, inotropic, and arrythmogenic effects of coronary
flow, Am. J. Physiol. Heart Circ. Physiol. 278 (1) (2000)
H106–16.
[62] R. Bhardwaj, C.P. Page, G.R. May, P.K. Moore,
Endothelium-derived relaxing factor inhibits platelet aggre-
gation in human whole blood in vitro and in the rat in vivo,
Eur. J. Pharmacol. 157 (1) (1988) 83–91.
[63] Y. Zeng, J.M. Tarbell, The adaptive remodeling of endothelial
glycocalyx in response to fluid shear stress, PLoS One 9 (1)
(2014), e86249.
[64] A.M.W. Bartosch, R. Mathews, J.M. Tarbell, Endothelial
Glycocalyx-mediated nitric oxide production in response to
selective AFM pulling, Biophys. J. 113 (1) (2017) 101–108.
[65] E.E. Ebong, S.V. Lopez-Quintero, V. Rizzo, D.C. Spray, J.M.
Tarbell, Shear-induced endothelial NOS activation and
remodeling via heparan sulfate, glypican-1, and syndecan-
1, Integr Biol (Camb) 6 (3) (2014) 338–347.
[66] X.Z. Zheng, J. Wu, Q. Zheng, W.Z. Zha, Coronary sinus flow
is reduced and recovered with time in viral myocarditis
mimicking acute coronary syndrome: a transthoracic Doppler
echocardiographic study, J. Ultrasound Med. 35 (1) (2016)
63–69.
[67] D.R. Potter, J. Jiang, E.R. Damiano, The recovery time
course of the endothelial cell glycocalyx in vivo and its
implications in vitro, Circ. Res. 104 (11) (2009) 1318–1325.
[68] M. Radu, J. Chernoff, An in vivo assay to test blood vessel
permeability, J. Vis. Exp. 73 (2013) e50062.
[69] E.G. Perdiguero, A. Galaup, M. Durand, J. Teillon, J.
Philippe, D.M. Valenzuela, A.J. Murphy, G.D. Yancopoulos,
G. Thurston, S. Germain, Alteration of developmental and
pathological retinal angiogenesis in angptl4-deficient mice, J.
Biol. Chem. 286 (42) (2011) 36841–36851.
34 SPARC preserves endothelial glycocalyx integrity
